CD47 and cancer: These include approaches that aim at inhibiting the CD47 “don’t-eat-me” signal produced by cancer cells and/or the SIRPα receptor for CD47 on macrophages, as well as stimulation of Toll-like receptor (TLR) signaling with TLR agonists (55).